CHG-2024-0121
Formulation Change for Kcluximab. Specification Change for Kcluximab — minor update. Impacts 5 markets and 5 variations.
Change Number
CHG-2024-0121
Type
Formulation Change
Product
Status
Active
Owner
Marcus Webb
Initiated
2023-01-21
Description
Specification Change for Kcluximab — minor update
Impacted Markets (5)
FR — FranceNL — NetherlandsTR — TurkeyPT — PortugalDK — Denmark
Impacted Modules
3.2.P.34.2.1
Linked Variations (0)
| Variation # | Type | Application | Status | Submitted | Approved |
|---|